[go: up one dir, main page]

WO2004073731A8 - 14-3-3 protein for prevention and treatment of fibroproliferative disorders - Google Patents

14-3-3 protein for prevention and treatment of fibroproliferative disorders

Info

Publication number
WO2004073731A8
WO2004073731A8 PCT/CA2004/000245 CA2004000245W WO2004073731A8 WO 2004073731 A8 WO2004073731 A8 WO 2004073731A8 CA 2004000245 W CA2004000245 W CA 2004000245W WO 2004073731 A8 WO2004073731 A8 WO 2004073731A8
Authority
WO
WIPO (PCT)
Prior art keywords
relates
prevention
treatment
skip
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2004/000245
Other languages
French (fr)
Other versions
WO2004073731A1 (en
Inventor
Aziz Ghahary
Edward E Tredget
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP04712453A priority Critical patent/EP1603586A1/en
Publication of WO2004073731A1 publication Critical patent/WO2004073731A1/en
Publication of WO2004073731A8 publication Critical patent/WO2004073731A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates generally to methods for the prevention and/or treatment of fibroproliferative disorders in a mammal. More particularly, this invention relates to 14-3-3 proteins which mediate collagenase expression and content of the tissues and organs of a mammal. It also relates to a method of increasing the collagen content of the skip of a mammal. Furthermore it relates to the prevention, alleviation and/or treatment of skip having a low collagen content. The invention also relates to a method of screening for compounds that are capable of increasing the collagen content of the skip, and to compounds identified by said method. The invention also discloses combinations of a weak acid proteins with 14-3-3 that provides complimentary fibroproliferative therapy.
PCT/CA2004/000245 2003-02-19 2004-02-19 14-3-3 protein for prevention and treatment of fibroproliferative disorders Ceased WO2004073731A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04712453A EP1603586A1 (en) 2003-02-19 2004-02-19 14-3-3 protein for prevention and treatment of fibroproliferative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44770203P 2003-02-19 2003-02-19
US60/447,702 2003-02-19

Publications (2)

Publication Number Publication Date
WO2004073731A1 WO2004073731A1 (en) 2004-09-02
WO2004073731A8 true WO2004073731A8 (en) 2004-10-28

Family

ID=32908483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000245 Ceased WO2004073731A1 (en) 2003-02-19 2004-02-19 14-3-3 protein for prevention and treatment of fibroproliferative disorders

Country Status (2)

Country Link
EP (1) EP1603586A1 (en)
WO (1) WO2004073731A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030538A1 (en) * 2004-07-21 2006-02-09 Medtronic, Inc. Methods for reducing or preventing localized fibrosis using SiRNA
EP1778310A2 (en) 2004-07-21 2007-05-02 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
PE20071309A1 (en) * 2006-02-17 2008-02-13 Wyeth Corp ANTIBODIES FOR BONE FORMATION MODULATION
WO2020102623A1 (en) * 2018-11-15 2020-05-22 The University Of Toledo Materials and methods for the prevention of rheumatoid arthritis
CN117899196B (en) * 2024-03-18 2024-06-04 中国人民解放军总医院第一医学中心 Application of 14-3-3zeta protein or YWHAZ gene in cornea injury treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2250983T3 (en) * 1995-12-26 2006-04-16 Teikoku Seiyaku Kabushiki Kaisha USE OF ACETILSALICILIC ACID IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF SKIN INJURIES.
US6335156B1 (en) * 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle

Also Published As

Publication number Publication date
EP1603586A1 (en) 2005-12-14
WO2004073731A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
GEP20166454B (en) Sclerostin binding agents
WO2006119467A3 (en) Protein activity modification
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
DE602004014117D1 (en) THIAZOLE FOR USE AS INHIBITORS OF PROTEIN KINASES
WO2008080045A3 (en) Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
WO2007149293A3 (en) Transgenic flies expressing tau and amyloid precursor fragment
WO2007084986A3 (en) Compositions and methods for preventing or treating feline chronic kidney disease
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
DE602004012578D1 (en) PYROME COMPOSITIONS SUITED AS INHIBITORS OF C-MET
WO2006102283A3 (en) Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2008051326A3 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
WO2006071952A3 (en) Compositions and methods for improving kidney function
WO2005115548A3 (en) Treating depressive disorders with carbonic anhydrase activators
WO2006122046A3 (en) Vascular disease therapies
WO2004073731A8 (en) 14-3-3 protein for prevention and treatment of fibroproliferative disorders
WO2005017187A3 (en) Methods for screening and identifying compounds
WO2006132739A3 (en) Novel chemical compounds
ATE494903T1 (en) USE OF SLURP-1 TO TREAT DISEASES CAUSED BY ACETYLCHOLINE RECEPTOR DISRUPTIONS
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2007079141A3 (en) Method of identifying compounds useful to treat neuronal degenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2004712453

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004712453

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004712453

Country of ref document: EP